The Liver Cancer Market is expected to grow due to rising incidence rates, targeted therapies, and improved early detection

The global liver cancer market size was worth around USD 6.41 billion in 2023 and is predicted to grow to around USD 14.64 billion by 2032 with a compound annual growth rate (CAGR) of roughly 9.60% between 2024 and 2032.

Liver cancer is a serious medical condition in which malignant cells develop in the liver, one of the body's most important organs responsible for filtering blood, producing bile for digestion, and performing hundreds of other metabolic functions. The most common form of liver cancer is hepatocellular carcinoma, which originates in the main type of liver cell called the hepatocyte. Another form, cholangiocarcinoma, begins in the bile ducts within or around the liver. Liver cancer is often associated with underlying conditions such as chronic hepatitis B or hepatitis C infection, cirrhosis caused by long-term alcohol use, or non-alcoholic fatty liver disease related to obesity and diabetes. Because symptoms in the early stages are usually mild or absent, many patients are diagnosed only after the disease has already progressed significantly. Treatment depends on disease stage and patient health, including surgery, liver transplant, ablation, chemotherapy, radiation, and targeted or immunotherapy. Research in liver cancer treatment has advanced considerably in recent years, with several new drug approvals offering improved survival outcomes for patients with advanced disease.

The liver cancer market is growing due to increasing global rates of hepatitis infection and liver disease, rising awareness of early screening, and continued development of effective targeted and immunotherapy treatment options.

Browse the full “Liver Cancer Market By Treatment (Targeted Therapy, Radiation Therapy, Surgery, Chemotherapy, and Immunotherapy), By Stage of the Cancer (Advanced Stage, Intermediate Stage, and Early Stage), By Disease Type (Hepatoblastoma, Intrahepatic Cholangiocarcinoma, Hepatocellular Carcinoma, and Fibrolamellar Carcinoma), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2024 - 2032” Report at https://www.zionmarketresearch.com/report/liver-cancer-market

Market Growth Factors

Several important factors are accelerating development and investment in the liver cancer market.

• High global disease burden: Liver cancer is one of the most common and deadly cancers worldwide, especially in regions with high hepatitis infection rates.
• Immunotherapy breakthroughs: New immunotherapy drugs and combination treatments are improving survival rates, encouraging more research and investment in advanced liver cancer care.
• Improved screening programs: Expanded screening in high-risk groups helps detect liver cancer earlier, enabling more patients to receive timely, effective treatment.

Restraints

• Late-stage diagnosis: Liver cancer often shows very few early symptoms, so many patients are diagnosed late, when treatment options are limited.
• Liver toxicity challenges: Many patients already have damaged liver function, making it difficult to use strong treatments or higher drug doses safely.

Liver Cancer Market: Report Scope

Market Segmentation

The liver cancer market can be segmented by cancer type, treatment type, end user, diagnosis method, and region.

Based on cancer type, the market is divided into hepatocellular carcinoma, cholangiocarcinoma, and others. Hepatocellular carcinoma leads the market by a wide margin as it accounts for approximately 75 to 85 percent of all primary liver cancer cases diagnosed each year globally.

Based on treatment type, the liver cancer market is classified into surgery, ablation therapy, radiation therapy, targeted therapy, immunotherapy, and chemotherapy. Targeted therapy is the fastest-growing segment, driven by the approval and adoption of several new small-molecule drugs and antibody treatments that specifically target cancer cells while sparing healthy tissue.

Based on end user, the market is segregated into hospitals, oncology specialty centers, and research institutes. Hospitals hold the largest share as they provide the full range of diagnostic imaging, surgical, and medical oncology services required for comprehensive liver cancer care.

Based on the diagnosis method, the liver cancer industry is categorized into imaging tests, biopsy, and blood tests. Imaging tests lead the segment as they are widely used for early detection, disease monitoring, and treatment planning through techniques such as CT scans and MRI.

The Asia Pacific leads the liver cancer market due to a high number of cases and a strong healthcare focus in the region. Countries like China, Japan, and India have large populations affected by risk factors such as hepatitis B and C infections. This increases the demand for early diagnosis and treatment. Governments are also running screening programs to detect liver cancer at earlier stages. Hospitals and research centers in the region are adopting advanced treatments like targeted therapy and immunotherapy. In addition, improving healthcare infrastructure and rising awareness about liver diseases are helping the Asia Pacific maintain its leading position in the liver cancer market.

Key Market Players

Leading companies operating in the global liver cancer market include:

• Novartis AG
• Bristol-Myers Squibb
• Celsion Corporation
• Johnson & Johnson
• Merck & Co.
• Eli Lilly and Company
• Bayer AG
• Amgen Inc.
• Roche
• Sanofi
• Pfizer Inc.
• AbbVie Inc.
• Eisai Co. Ltd.
• AstraZeneca
• Exelixis Inc.

Recent Developments

• In April 2026, AstraZeneca announced that its combination therapy with Imfinzi showed significant improvement in progression-free survival in a late-stage liver cancer trial, highlighting advances in immunotherapy.
• In January 2026, Elevar Therapeutics reported that the U.S. FDA accepted its resubmitted application for rivoceranib in combination with camrelizumab as a first-line treatment for advanced hepatocellular carcinoma, with a target decision date set for mid-2026.

The global liver cancer market is segmented as follows:

By Treatment

• Targeted Therapy
• Radiation Therapy
• Surgery
• Chemotherapy
• Immunotherapy

By Stage of the Cancer

• Advanced Stage
• Intermediate Stage
• Early Stage

By Disease Type

• Hepatoblastoma
• Intrahepatic Cholangiocarcinoma
• Hepatocellular Carcinoma
• Fibrolamellar Carcinoma

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.co